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doi:10.1016/j.jfma.2011.10.006Background/Purpose: Pneumococcal diseases caused by Streptococcus pneumoniae can lead
to significant morbidity and mortality in young infants and the elderly. The seven-valent pneu-
mococcal conjugate vaccine (PCV7) has been available on the private market in Taiwan since
October 2005. To date, there has not been any cost-effectiveness analysis (CEA) of PCV7 in
Taiwan. A pharmacoeconomic model populated with local parameters is needed for vaccine
decision-making. The aim of the study was to provide a CEA of PCV7 in Taiwan and explore
the impact of herd effect and indirect cost on the findings of CEA.
Methods: A decision analytic model was populated with local epidemiological and economic
data to simulate the expected clinical and economic outcomes from a hypothetical vaccinated
birth cohort of 191,310 infants compared to no vaccination over a 10-year time horizon. To
explore the impact of herd effect, results were presented with and without herd effect. More-
over, the study was conducted from both payer and societal perspectives to examine the
impact of indirect cost. One-way sensitivity analyses were performed to evaluate model
robustness. The cost-effectiveness of a reduced three-dose schedule was also estimated.
Results: PCV7 vaccination could prevent 1281 cases of invasive pneumococcal diseases,
178,145 cases of all-cause hospitalized pneumonia, 69,962 cases of all-cause acute otitisformatics and Medical Statistics Research Center, 259 Wen-Hwa 1st Road, Kwei-Shan Taoyuan
.edu.tw (C.J. Chang).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
152 D.B.C. Wu et al.media, and 981 deaths over a 10-year time horizon. The vaccination program with an annual
cost of NT$1,950.5 million could lead to 15.4% reduction in direct medical costs of NT$6,010
million and 64.1% reduction in indirect costs of NT$9,467 million. The vaccination with
a four-dose schedule would lead to an incremental cost of NT$1,183,028 per life-year gained
from the payer perspective and NT$619,862 per life-year gained from the societal perspective.
Conclusion: Taking herd effect and indirect costs into account, PCV7 vaccination is cost-
effective in Taiwan. Further pharmacoeconomic model should include herd effect in CEA of
infectious disease research.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Streptococcus pneumoniae is a bacterial pathogen respon-
sible for significant morbidity and mortality worldwide.
Infection with S pneumoniae may be invasive (meningitis
and bacteremia, collectively reported as IPD) or noninva-
sive (non-bacteremic pneumonia and otitis media)
depending on the site of infection. In Taiwan, pneumo-
coccal disease is a major healthcare burden, particularly in
young children and the elderly.1,2 Since October 2007, IPD
has been a notifiable disease to the Centers for Disease
Control (CDC) in Taiwan.
While penicillin remains the drug of choice for patients
with pneumococcal disease, the growing incidence of
penicillin-resistant S pneumoniae is a concern worldwide
and has complicated disease management.3 Furthermore,
studies have shown that patients with resistant pneumo-
coccal infections often require longer hospital stays and
greater resource utilization to manage their condition,
highlighting the potential economic consequences of
increasing resistance rates of this bacterium.4,5 A study in
Taiwan indicated that 80.7% of S pneumoniae isolates ob-
tained from children under 14 years of age were found to be
resistant to penicillin (intermediate resistance 16.3% and
resistant 67.4%).6 Such rates indicate that despite the
implementation of stringent antibiotic prescribing proto-
cols, Taiwan has one of the highest rates of antibiotic
resistant S pneumoniae globally.
The pneumococcal conjugate vaccine has been consid-
ered a priority for inclusion in national childhood immuni-
zation programs by the World Health Organization (WHO)
since 2007, with an aim to reduce the burden of pneumo-
coccal diseases worldwide.7 Although there are around 90
known serotypes of S pneumoniae, most pneumococcal
diseases are only caused by a few serotypes.8 Providing
immunologic protection against these serotypes could
protect against the majority of S pneumoniae-related
infections. In view of this, vaccines to provide protection
against some of the most common serotypes have been
developed, including the seven-valent pneumococcal
conjugate vaccine (PCV7), a heptavalent conjugate vacci-
ne that contains saccharides of the capsular antigen of
S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
individually conjugated to a diphtheria CRM197 protein. The
effects of this vaccine have been studied in Taiwan, with
results indicating that it is considered to be efficacious and
safe in Taiwanese children.9 However, judging from the
already crowded vaccination schedules in the NationalImmunization Program (NIP), decision-making in regards to
introducing new vaccines into the NIP has been gradually
emphasized and will require an economic evaluation to
achieve this goal. Therefore, the role of CEA in health
economics has gained its spotlight in decision-making of
newly developed vaccines in various countries. In addition
to the hurdles of licensing a new vaccine, quality control,
manufacturing, and verifying its efficacy in clinical trial,
CEA of vaccine has been added as another hurdle which
provides important impact for its reimbursement in
government vaccination policy. In view of this, our CEA of
PCV7 in Taiwan will provide an important avenue to achieve
this goal.
In terms of the benefit of a national vaccination
program, in countries where PCV7 has been introduced into
the routine vaccination schedule, rates of pneumococcal
disease have decreased in not only vaccinated infants, but
also in the unvaccinated adult populations.10e13 This
effect, referred to as “herd protection,” occurs when
vaccination reduces the spread of a pathogen from infants
to unvaccinated children and adults and in turn reduces
their risk of contracting a disease. It has been shown by the
US Centers for Disease Control and Prevention Active
Bacterial Core Surveillance that the elderly above 65 years
of age can benefit indirectly from the universal infant PCV7
vaccination through the well-known herd effect as a kind of
indirect protection of unvaccinated susceptible individuals
with lower risk to be infected with the disease.14 A long-
term observational study in the US indicated that the
childhood PCV7 vaccination was estimated to prevent
around 38,000 cases of IPD among a vaccinated cohort for
the first 5 years after vaccination with US$112,000 per life
year saved. If further considering herd effect, the vacci-
nation prevented additional 109,000 cases of IPD and led to
smaller incremental cost-effectiveness ratio (ICER) of
US$7500 per life year saved. Therefore, the impact of herd
effect on economic evaluation of a vaccine is huge.
TheAdvisory Committee on Immunization Practices (ACIP)
in Taiwanwas established under the CDC in 1986. Themission
of the ACIP is to provide important advice such as general
criteria for a vaccine to be included for the NIP according to
disease burden and public health nature of the infection and
vaccine procurement funding and to convey timely advice on
specific vaccine in case of unexpected and sudden disease
outbreak. Nevertheless, with limited medical resources, the
growing pressure of healthcare expenditure has made CEA of
vaccine a vital issue within the operational framework of the
ACIP. The independent health economic assessment from
Cost-effectiveness analysis of PCV7 in Taiwan 153using pharmaecoeconomic model will provide decision
makers such as the ACIP with more scientific evaluation of
a particular national vaccination program in order to allocate
medical resources in a more efficient manner. In view of this,
an economic evaluation of the cost-effectiveness of universal
infant vaccination with PCV7 will be useful to guide reim-
bursement decisions about including the vaccine in the NIP in
Taiwan. Although cost-effectiveness analyses of PCV7 have
been undertaken in other countries, their findings cannot be
generalized in the context of Taiwan due to differences in
disease epidemiology, serotype prevalence, medical costs,
and clinical practice, which are major inputs for a vaccine
pharmacoeconomic model. Therefore, the objective of this
study was to populate the pharmacoeconomic model with
local parameters collected from various sources such as large
database, randomized clinical trials, observational studies,
case-control studies, and local experts’ opinions in order to
acquire country-specific outcomes. The second objective of
the study was to provide an economic evaluation of universal
infant PCV7 vaccination in Taiwan and explore the impact of




To estimate the long-term outcomes associated with
vaccination, an age-stratified decision analytic model was
adapted to simulate the expected health outcomes result-
ing from universal PCV7 vaccination of a birth cohort of
191,310 Taiwanese infants compared with no vaccination
over a 10-year time horizon.15 The decision tree analysis is
a kind of scenario analysis. In the branch with the absence
of vaccination, we assume a hypothetical cohort to repre-
sent newly born infants free of pneumococcal diseases in
the year of 2009 but will later be likely infected with the
diseases. In another branch with vaccination, another
identical hypothetical cohort of newly born infants is
assumed to be infected with pneumococcal diseases with
lower risk. Vaccine efficacy rates against four types of
pneumococcal disease, including pneumonoccal meningitis,
pneumococcal bacteremia, all-cause hospitalized pneu-
monia, and all-cause acute otitis media (AOM), were
included in the model to calculate the lower risk of disease
contraction.
Demographic data
Population data stratified by age groups, non-S. pneumo-
niae-related mortality rates, and the life years lost in each
age group due to S pneumoniae-related deaths were
derived from Taiwan government sources.16 Details are
presented in Table 1.
Epidemiological data
The epidemiological parameters used in this study and
their respective sources are summarized in Table 1.
Average age-specific incidence rates for IPD,hospitalized all-cause pneumonia, and all-cause AOM
were estimated using data from the National Health
Insurance Research Database (NHIRD; 2002e2004) to
represent the pre-vaccination disease trends before
PCV7 introduction into the private market in Taiwan in
2005. As there is no microbiological information from
NHIRD, we used defined ICD9 codes in NHIRD to capture
disease cases: 320.1 for pneumococcal meningitis;
038.2, 038.9, and 790.7 for pneumococcal bacteremia
excluding 482, 486, and 510.9; 481e486 and 4870 for all-
cause pneumonia; 381, 381.0, 382, 382.0, 382.4, 382.9,
and 384.0 for AOM. Mortality due to microbiologically
confirmed IPD was estimated using the CDC database.17
Mortality due to all-cause hospitalized pneumonia was
obtained from the NHIRD using the NHIRD death code
before hospital discharge.Cost data
The average direct medical costs of pneumococcal
diseases were determined from the payer perspective
using the NHIRD (2002e2004), to represent the costs borne
by the Taiwanese healthcare system. These costs cover
the direct medical resources consumed in the treatment
of pneumococcal disease, including hospitalization,
healthcare professional consultation fees, intensive care
admissions, medications, and diagnostic tests. Using the
same set of ICD9 codes, the average annual direct cost for
a particular pneumococcal disease was estimated by
dividing the total direct cost of a pneumococcal disease
by the total number of episodes for those 3 years
(2002e2004).
An analysis which included costs determined from
a societal perspective was also conducted, which included
both direct medical costs, and indirect costs such as the
cost of productivity lost by a patient due to either non-
fatal pneumococcal diseases or premature death, and
caregiver time. Indirect costs were estimated using the
human capital approach.18 Using this approach, it was
assumed that a half-day of work time was lost for each
outpatient visit and a full-day of work time was lost for
each day of hospitalization. For children under 18 years of
age with a pneumococcal infection, one parent was
assumed to miss work for the child’s outpatient or inpa-
tient visits. Full-time employment was assumed for people
18e65 years of age. The cost of work loss for parents can
then be estimated using wage information from the web-
site of Directorate General of Budget, Accounting and
Statistics, Executive Yuan in Taiwan.19 If an adult is
infected with the disease, then his or her length of stay in
hospital multiplied by the daily wage obtained from the
same government website can be used to estimate the cost
of work loss of each patient. The expected cost of
productivity lost due to pneumococcal death was esti-
mated by multiplying the life expectancy of a patient
(derived from the median age of death for each age
group), with the average annual earnings for the corre-
sponding age group.19 Transportation cost is assumed to be
NT$100 for both children and adults. The breakdown of the
individual costs included in the model and their data
sources are presented in Table 2.
Table 1 Age-specific epidemiological parameters.
Base-case epidemiological parameters
Base-case estimates Range Source
Demographic data
Newly born infants at 2009 189,500 Not varied [16]
Life expectancya 75 Not varied [16]
Epidemiological data (per 100,000)a
Incidence of meningitis 2.5  50% NHIRD
Incidence of bacteremia 5.6  50% NHIRD
Incidence of pneumonia 3445.9  50% NHIRD
Incidence of AOM 23,005.9 50% NHIRD
Mortality rates of meningitis 0.48 50% [17]
Mortality rates of bacteremia 0.48 50% [17]
Mortality rates of pneumonia 0.035 50% NHIRD
Mortality rates of AOM 0 Not varied NHIRD
Vaccine efficacy data (four-dose schedule)
Serotype coverage of PCV7 0.64 Not varied [21]
Efficacy against IPDa 0.94 50% [20]
Efficacy against pneumoniaa 0.255 50% [22]
Efficacy against AOMa 0.07 50% [23]
Herd effect
Herd effect against IPD (20e39 y) 0.32 Varied by 95% CI boundsb [11]
Herd effect against IPD (40e64 y) 0.8 Varied by 95% CI boundsb [11]
Herd effect against IPD (65 y) 0.18 Varied by 95% CI boundsb [11]
Herd effect against pneumonia (20e39 y) 0.26 Varied by 95% CI boundsc [24]
Herd effect against pneumonia (40e64 y) 0.19 Varied by 95% CI boundsc [24]
Herd effect against pneumonia (65 y) 0.15 Varied by 95% CI boundsc [24]
Vaccine coverage 90% Not varied Assumption
Vaccine-immunity period (y) 5 Not varied Assumption
a Estimates for children aged 0e2 years. In the model, estimates varied by age.
b Lower bound of 95% confidence interval (CI) of estimate of herd effect are 23% (20e39 years), 1% (40e64 years), and 11% (65 years);
upper bound of 95% CI of estimate of herd effect are 41% (20e39 years), 20% (40e64 years), and 31% (65 years).
c Lower bound of 95% confidence interval (CI) of estimate of herd effect are 4% (20e39 years), e3% (40e64 years), and e2% (65
years); upper bound of 95% CI of estimate of herd effect are 43% (20e39 years), 35% (40e64 years), and 30% (65 years).
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Vaccine efficacy against IPD was derived from the Northern
California Kaiser Permanente pivotal trial.20 The average
efficacy rate of PCV7 against IPD was calculated by multi-
plying the efficacy of PCV7 seen in the Intent-to-Treat
group in the Northern California Kaiser Permanente trial
d i.e., 94%, with the expected coverage of PCV7 in Taiwan
against the seven vaccine serotypes.21 The efficacy of PCV7
against all-cause hospitalized pneumonia was estimated to
be 25.5% in line with a study which assessed vaccine effi-
cacy against pneumonia confirmed using WHO-standardized
methodology.22 The efficacy of PCV7 against AOM was
estimated to be 7%, in line with the Finnish Otitis Media
vaccine trial.23 Vaccine-induced immunity was assumed to
wane by 1% per year for the first 5 years following initial
vaccination and by 3% annually for years 6e10.14
Herd effect data
Age-specific estimates of the anticipated herd effect of
PCV7 on unvaccinated adult populations were consideredby calculating the expected reduction in adult cases of IPD
in line with the published rates from the US experience.11
The midpoint estimates for the herd effect in each age
group were used in the primary analysis: 32% (range
23e41%) for adults aged 20e39 years, 8% (range 1e20%) for
adults aged 40e64 years, and 18% (range 11e31%) for adults
aged 65 years. A reduction in the number of cases of
hospital-treated pneumonia in adults was also assumed to
occur from the herd effect, with rates appropriated from
published literature: 26% (range 4e43%) for adults aged
20e39 years, 19% (range -3% to 35%) for adults aged 40e64
years, and 15% (range -2% to 30%) for adults aged 65
years.24 Data on the possible herd effect of PCV7 vaccina-
tion on adult cases of AOM were not evident, and hence
herd effect on adult AOM was not considered in the study.
Cost of PCV7 vaccination program
The cost of introducing a universal vaccination program
included both PCV7 acquisition and administration costs.
The acquisition cost of PCV7 was assumed to be NT$2500
(US$78.5) per dose, as the current price of the vaccine in
Table 2 Age-specific cost parameters.
Base-case cost parameters
Children Adult Dist/range Source
Direct medical cost
Average cost of treating per meningitis episode $196,875 $81,652 50% NHIRD
Average cost of treating per bacteremia episode $110,861 $66,064 50% NHIRD
Average cost of treating per pneumonia episode $18,982 $25,450 50% NHIRD
Average cost of treating per AOM episodea $1,624 d 50% NHIRD
Indirect cost
Transportation cost per travel $100 50% Assumption
Cost of work loss due to per SP infection
Meningitis $17,327 $12,139 50% [19]
Bacteremia $14,869 $10,318 50% [19]
Pneumonia $6,832 $6,595 50% [19]
AOM $4,750 $3,986 50% [19]
Cost of productivity loss
All pneumococcal diseases $9,998,892 $4,151,635 50% [19]
Vaccine cost
Cost of vaccine (per dose) $2,500 50% Assumption
Cost of vaccine administration (per dose) $150 50% Assumption
Discount rate 3% 0% vs. 6% [18]
a Due to the low incidence of AOM in older children and adults, we assume that persons aged 10 years are not at risk of AOM.
Cost-effectiveness analysis of PCV7 in Taiwan 155the private market. The cost of vaccine administration was
estimated to be NT$150 (US$4.7) per dose. All currency
conversion was based on 2009 US$.25
Vaccination administration
A four-dose vaccination schedule was assumed for the birth
cohort (i.e., infants less than 6 months of age) in the base-
case analysis, as a primary series of three doses at 2, 4, and
6 months of age, and a booster (fourth) dose administered
in the second year of life at 12e15 months of age. A
reduced three-dose schedule was also analyzed in scenario
secondary analysis. A vaccination coverage rate of 90% was
assumed for all newly born infants in line with the US
Department of Health’s goal of achieving 90% coverage
rates for all routine childhood vaccinations by 2010.26
Cost-effectiveness analysis
The cost-effectiveness of a universal PCV7 vaccination








DCZCvac  Cnone Z incremental cost (vaccination vs. no
vaccination);
DEZEvac  Enone Z incremental effectiveness (vaccina-
tion vs. no vaccination).
If effectiveness refers to life year, then ICER can be
interpreted as incremental cost per life-year gained (LYG).Life-years were used to measure deaths avoided, where
each death prevented at a certain age group was equated
to a certain number of life years, depending on the age at
which the death was expected to occur and the life
expectancy of the individual. For example, each childhood
death avoided in Taiwan was equal to the life expectancy at
birth (approximately 75 years) minus the child’s age at the
time of death. A discount rate of 3% was applied to both
costs and benefits in the base-case analysis.
As yet, there is no explicit threshold value for cost per
life-year gained in Taiwan. However, the World Health
Organization CHOICE (CHOosing Interventions that are Cost-
Effective) group has developed guidelines on generalized
cost-effectiveness analyses for public health interventions
and indicates that interventions which cost less than three
times the average per capita income per outcome unit are
cost effective. With respect to this threshold, universal
PCV7 vaccination would be considered cost-effective in
Taiwan if the incremental cost per life-year gained is below
NT$2,704,410 (using the 2009 GDP per capita of
NT$901,470) either in the payer or the societal perspective.Sensitivity analysis
A series of one-way sensitivity analyses were performed to
evaluate the sensitivity of the findings to plausible variation
in specific data inputs. Parameters were varied by 50%
from the base-case estimates. The estimates of the herd
effect were varied between the lower and upper bounds
surrounding their 95% confidence intervals. The results are
presented in a tornado diagram (Fig. 1). Since the objective
of this study was to consider the cost-effectiveness of PCV7
vaccination, with and without a herd effect, a conventional
Figure 1 One-way deterministic sensitivity analyses. The tornado diagram shows the results of a representative one-way
sensitivity analysis for the impact of model parameters on incremental cost-effectiveness ratio (ICER). Plausible variations in
the base-case assumptions produced changes in the ICER, with the ranges listed on the x-axis. The vertical solid line represents the
base-case ICER under a four-dose vaccination schedule from the societal perspective.
Table 3 Estimated clinical outcomes: cases, deaths, and






Meningitis 16 9 7
Bacteremia 82 39 43
Pneumonia 68,560 54,778 13,782
AOM 1,218,315 1,148,353 69,962
Death 136 95 41
Life years lost 4,164 2,895 1,269
Herd effect (by age groups)
Meningitis
2034 600 408 192
35e64 600 552 48
65þ 690 566 124
Bacteremia
20e34 980 666 314
35e64 1,860 1,711 149
65þ 2,250 1,845 405
Pneumonia
20e34 142,728 105,619 37,109
35e64 142,822 115,686 27,136
65þ 667,450 567,333 100,118
AOMa d d d
Death
20e34 425 289 136
35e64 647 595 52
65þ 4,177 3,425 752
Life years lost 77,395 62,469 14,926
a Due to the low incidence of AOM in older children and
adults, we assume that persons aged 10 years are not at risk of
AOM.
156 D.B.C. Wu et al.CEA was considered the most valid approach, and a proba-
bilistic sensitivity analysis (PSA) was therefore not con-




The clinical impact of PCV7 vaccination with respect to
the number of cases of pneumococcal disease and deaths
avoided in both the birth cohort and the unvaccinated
age-stratified adult populations are presented in Table 3.
In the birth cohort alone, universal PCV7 vaccination was
estimated to prevent 50 cases of IPD (7 cases of meningitis
and 43 cases of bacteremia), 13,782 cases of all-cause
hospitalized pneumonia, 69,962 cases of AOM, and 41
deaths, equivalent to a gain of 1269 life-years. With the
inclusion of the herd effect, a total of 14,926 life-years
were gained through the prevention of an additional 364
cases of meningitis (192 cases in the 20e34 age group; 48
cases in the 35e64 age group; 124 cases in the 65þ age
group), 867 cases of bacteremia (314 cases in the 20e34
age group; 149 cases in the 35e64 age group; 405 cases in
the 65þ age group), 164,363 cases of all-cause hospital-
ized pneumonia (37,109 cases in the 20e34 age group;
27,136 cases in the 35e64 age group; 100,118 cases in the
65þ age group), and 940 deaths (136 deaths in the 20e34
age group; 52 deaths in the 35e64 age group; 752 deaths in
the 65þ age group) in the unvaccinated adult population.
Among the three age groups, herd effect is most influen-
tial in the 65þ age group, followed by the 20e34 age
group, and the 35e64 age group. This is reasonable in that
the 65þ age group is another high-risk group for pneu-
mococcal infection.
Cost-effectiveness analysis of PCV7 in Taiwan 157Economic outcomes
A summary of treatment costs saved as a result of PCV7
vaccination in terms of direct cost and indirect costs is
presented in Table 4, where results of direct and herd
effect are displayed separately. Over a 10-year time
horizon, the implementation of a universal infant PCV7
vaccination program requires an annual cost of NT$1,950.5
million (US$61.26 million). Considering direct medical
cost, NT$346 million (US$10.87 million) can be saved
due to direct effect, and an additional NT$5,663 million
(US$177.87 million) can be saved due to herd effect
(NT$10.78 million in the 20e34 age group; NT$19.08 million
in the 35e64 age group; NT$148.02 million in the 65þ age
group), resulting in a total saving of NT$6,010 million
(US$188.75 million) in all age groups. In terms of indirect
cost, NT$638 million (US$20.04 million) can be saved due to
direct effect and an additional NT$2,819 million (US$612.61
million) can be saved due to herd effect (NT$270 million in
the 20e34 age group; NT$269 million in the 35e64 age
group; NT$2,280 million in the 65þ age group), leading to
a total saving of NT$3,457 million (US$612.61 million) in all
age groups.
Cost-effectiveness results
The base-case cost-effectiveness outcomes with and
without herd effect are shown in Table 5. Without the
inclusion of herd effect, assuming a four-dose vaccination
schedule, PCV7 vaccination will have an ICER of
NT$15,093,230 (US$474,034) in payer perspective and
NT$14,590,626 (US$458,248) in societal perspective.
Reducing the total vaccination cost by 25% (i.e., a three-
dose vaccination schedule), the vaccination will lead to
a lower ICER of NT$11,251,735 (US$353,384) in payerTable 4 Estimated economic outcomes: direct and indi-









0e10 $2,985 $2,638 $346
Herd effect
(by age groups)
20e34 $1,288 $945 $343
35e64 $3,326 $2,719 $607
65þ $31,363 $26,650 $4,713
Indirect cost
Direct effect
0e10 $2,323 $1,685 e$638
Herd effect
(by age groups)
20e34 $2,345 $2,075 e$270
35e64 $2,234 $1,965 e$269




Total cost $53,729 $63,768 $10,039perspective and NT$10,434,018 (US$327,702) in societal
perspective. Accounting for herd effect, and assuming
a four-dose vaccination schedule, universal vaccination
with PCV7 is expected to have an incremental cost of
NT$1,183,028 (US$37,155) per LYG from the payer
perspective and NT$619,862 (US$19,468) per LYG from the
societal perspective. When a three-dose vaccination
schedule is assumed and the herd effect is taken into
account, universal vaccination with PCV7 has an incre-
mental cost of NT$422,671 (US$13,275) per LYG from the
payer perspective and NT$184,511 (US$5795) per LYG from
the societal perspective.
Sensitivity analyses
The results of the various one-way sensitivity analyses are
presented in a tornado diagram shown in Fig. 1. The ICER
was most sensitive to vaccine price, herd effect on pneu-
monia, mortality rate of pneumonia, and indirect cost of
pneumonia.
Discussion
This study is the first pharmacoeconomic evaluation con-
ducted on the predicted impact of infant vaccination with
PCV7 completed in Taiwan and serves as a useful example,
both in a local context and for other decision-makers in the
Asia Pacific region, on the potential benefits of introducing
this vaccine into the national childhood immunization
schedule. In this study, we populated a decision analytic
model with the most recent local epidemiological and cost
data available from the NHIRD, Taiwan CDC database, and
published literature to estimate country-specific clinical
and economic benefits, as well as the cost-effectiveness, of
universal PCV7 vaccination in Taiwan. The results of our
base-case analysis suggest that including a four-dose PCV7
vaccination program in the NIP in Taiwan will be a cost-
effective intervention in a payer perspective if herd effect
is taken into account according to WHO-recommended
threshold. When the indirect costs are considered in the
societal perspective, universal PCV7 vaccination program is
even more cost-effective, producing a more favorable ICER.
The three-dose vaccination program in both perspectives
will be more cost-effective compared to four-dose coun-
terparts. The exclusion of herd effect from the analysis
indicates that the vaccination program is not cost-effective
in both perspectives. Results from the one-way sensitivity
analyses showed that the key factor that had the greatest
impact on ICER was vaccine price. Herd effect on pneu-
monia, mortality rate of pneumonia, and indirect cost of
pneumonia also had considerable impact on ICER.
In several countries where PCV7 has been included in the
NIP, observational studies have indicated that the vacci-
nation of specific populations not only provides vaccinated
individuals with protection against pneumococcal disease,
but also reduces the risk of unvaccinated individuals
from developing both IPD and non-IPD.10 In the US, a post-
vaccination observational study estimated that PCV7
vaccination has prevented more than twice as many
cases of pneumococcal disease through the herd effect
than through its direct effect of protecting vaccinated
Table 5 Cost-effectiveness outcomes: incremental cost-effectiveness ratio (ICER) in both payer and societal perspectives and
for direct and herd effect, respectively.
Cost-effectiveness outcomes
Direct effect
Societal perspective (four-dose schedule) d d $14,590,626
Payer perspective (four-dose schedule) d d $15,093,230
Societal perspective (three-dose schedule) d d $10,434,018
Payer perspective (three-dose schedule) d d $11,251,735
Herd effect
Societal perspective (four-dose schedule) d d $619,862
Payer perspective (four-dose schedule) d d $1,183,028
Societal perspective (three-dose schedule) d d $184,511
Payer perspective (three-dose schedule) d d $422,671
158 D.B.C. Wu et al.children.20 In our study, we incorporated the estimates of
the herd effect seen in the US, in the absence of local data.
Our model attempted to mimic the benefit of herd effect by
assuming that the risk pneumococcal diseases in Taiwan
would decrease by the same proportion as was observed in
the US. Herd effect and indirect cost have been shown to
have enormous impact on the cost-effectiveness results in
this study. In terms of those two influential factors, the
findings of our study are consistent with the CEA of PCV7
conducted in other countries which showed that the clinical
benefit of the herd effect has been a major driver of cost-
effectiveness of the nationwide PCV7 vaccination program.
Several previous studies of PCV7 from Hong Kong, Germany,
the US, and the UK have also shown that the inclusion of
herd effect had led to a significant and consistent
improvement in cost-effectiveness results in favor of
universal vaccination with PCV7. In Hong Kong, PCV7
vaccination for 10 years will produce an ICER of US$6460
and US$5929 in both payer and societal perspectives,
respectively, when herd effect is considered. The exclusion
of herd effect will increase the ICER to US$260,523 and
US$246,353 in both payer and societal perspectives,
respectively. In Germany, it was estimated that the ICER of
only vaccinating children at high risk was US$53,603 and of
vaccinating the entire birth cohort was US$141,240 gained
without considering herd effect. If herd effect is consid-
ered, the ICER was greatly lowered to US$230.28 A study in
the US yielded an ICER of US$35,043 without herd effect
and US$11,089 if herd effect is considered.29 Another study
in England and Wales has also indicated a lower ICER from
US$158,700 to US$42,181, when herd effect was consid-
ered.30 A study in the UK suggested an ICER which
decreased from US$57,968 to US$21,863 when accounting
for herd effect.15
The NHIRD dataset contains data on ambulatory care,
inpatient care, dental services, and prescription drugs,
which have been collected for 96e99% of the population
since 1995. Given the high coverage rate of this database, it
was assumed that the data in our analyses were sufficiently
representative of the true clinical and economic conse-
quences of pneumococcal disease on a national level in
Taiwan. In addition, microbiologically confirmed cases of
IPD obtained from the Taiwan CDC database, which were
used to estimate age-specific IPD mortality rates, were also
considered reliable.As in any CEA, the overestimation or underestimation of
pharmacoeconomic results is driven, in part, by limita-
tions in the study design. In this study, we did not take
account for the fact that PCV7 vaccination might increase
carriage of non-vaccine serotypes. If an increase in non-
vaccine serotypes occurs, this may increase the overall
disease burden, in which case the observed effect of PCV7
against the disease burden may be reduced. This, in turn,
may worsen the cost-effectiveness of PCV7 (i.e., lead to
an increase in ICER). Another omission from our study,
which may lead to an overestimation of the effect of
vaccination, was the cost of potential adverse effects of
the PCV7 vaccine. In addition, costs associated with
running nationwide disease surveillance to monitor the
emergence of non-vaccine serotypes following vaccination
were also not considered due to the difficulty in esti-
mating these costs. Lastly, the benefit of vaccination was
quantified in terms of life years gained (without utility
weightings for each clinical presentation of pneumococcal
disease or their complications) instead of considering the
impact on quality of life. This outcome measure was
chosen in the absence of robust quality of life data for
infants in Taiwan.
On the other hand, there were several factors not
considered in the model which may have led to the
underestimation of some of the pharmacoeconomic results.
First, the potential effect of vaccination on other clinical
presentations of pneumococcal disease such as sinusitis and
septic arthritis was not included in the analysis. In addition,
the assumed incidence of pediatric pneumonia was
considered to be conservative, as only hospitalized cases
(i.e., severe cases) were included. It is likely that these
rates may underestimate the true burden of pneumonia
seen in the community. Second, the herd effect in older
children aged 10e19 years was not considered in this
analysis, as it was assumed that their disease burden would
be relatively low. Vaccination with PCV7 could also provide
protection against these aforementioned infections and
their inclusion in CEAs would likely further improve the
cost-effectiveness of the vaccine. Thirdly, the potential
cost savings from preventing complications of meningitis,
such as deafness, brain damage, focal neurological deficit,
and chronic seizures, were also not included in the present
analysis primarily due to a lack of local incidence and cost
estimates for these conditions.
Cost-effectiveness analysis of PCV7 in Taiwan 159Current international standards for conducting economic
evaluations recommend the use of multivariate PSA to
express parameter uncertainty.31 However, because the
objective of our study was to consider the cost-
effectiveness of PCV7 vaccination, with and without herd
effect and indirect cost, a conventional CEA is considered
appropriate, and the PSA is therefore not conducted to
avoid introducing more uncertainty into the model.
In line with many studies of PCV7 vaccination which have
beenconductedworldwide,7 theassumedherdeffectofPCV7
was the largest driver of uncertainty around the cost-
effectiveness results. The herd effect of vaccination
depends predominantly on population factors, such as social
contact structure and vaccination coverage rates, which vary
from country to country, and even within the same country
fromyear toyear.Therefore, it is possible that theherdeffect
observed in the US and used in our study may not accurately
reflect the local herd effects which would occur following
routine PCV7 vaccination of infants in Taiwan. Future
research will focus on developing a transmission dynamic
model to take account of the effects of PCV7 vaccination on
a local level and thereby acquire improvedcost-effectiveness
results of the impact of universal pneumococcal vaccination
in Taiwan. Despite the model choice, it is however suggested
that any further pharmacoeconomic model should always
include herd effect due to its huge impact when performing
a CEA in infectious disease research.
Universal infant PCV7 vaccination in Taiwan is expected
to lead to a substantial reduction in the incidence of
pneumococcal-related clinical presentations in both chil-
dren and adults. The cost savings resulting from both the
direct and herd effect of vaccination imply that PCV7 is
a cost-effective intervention with respect to the WHO’s
threshold for cost-effectiveness and a worthwhile invest-
ment to protect the Taiwan population against pneumo-
coccal disease.
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